The biologic revolution finally arrived for atopic dermatitis (AD) in 2017, with the approval of dupilumab, heralding a new era with many other agents in active development.1,2 Significant improvement in disease severity measures and a number of quality-of-life measures have raised the bar for AD treatment, mirroring the more stringent treatment goals that have been defined for patients with psoriasis.3
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Lio PA. Considerations in Weaning or Withdrawing Dupilumab Therapy—Nothing Is Forever. JAMA Dermatol. 2020;156(2):119–120. doi:10.1001/jamadermatol.2019.3331
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: